237 related articles for article (PubMed ID: 36278961)
1. Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer.
Peng K; Zhang F; Wang Y; Sahgal P; Li T; Zhou J; Liang X; Zhang Y; Sethi N; Liu T; Zhang H; Bass AJ
Clin Cancer Res; 2023 Jan; 29(1):197-208. PubMed ID: 36278961
[TBL] [Abstract][Full Text] [Related]
2. Gain-of-Function
Zhang H; Schaefer A; Wang Y; Hodge RG; Blake DR; Diehl JN; Papageorge AG; Stachler MD; Liao J; Zhou J; Wu Z; Akarca FG; de Klerk LK; Derks S; Pierobon M; Hoadley KA; Wang TC; Church G; Wong KK; Petricoin EF; Cox AD; Lowy DR; Der CJ; Bass AJ
Cancer Discov; 2020 Feb; 10(2):288-305. PubMed ID: 31771969
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors.
Marlowe TA; Lenzo FL; Figel SA; Grapes AT; Cance WG
Mol Cancer Ther; 2016 Dec; 15(12):3028-3039. PubMed ID: 27638858
[TBL] [Abstract][Full Text] [Related]
4. Recurrent RhoGAP gene fusion CLDN18-ARHGAP26 promotes RHOA activation and focal adhesion kinase and YAP-TEAD signalling in diffuse gastric cancer.
Zhang F; Sahu V; Peng K; Wang Y; Li T; Bala P; Aitymbayev D; Sahgal P; Schaefer A; Der CJ; Ryeom S; Yoon S; Sethi N; Bass AJ; Zhang H
Gut; 2024 Apr; ():. PubMed ID: 38621923
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.
Zhang H; Shao H; Golubovskaya VM; Chen H; Cance W; Adjei AA; Dy GK
Br J Cancer; 2016 Jul; 115(2):203-11. PubMed ID: 27336608
[TBL] [Abstract][Full Text] [Related]
6. Focal adhesion kinase-An emerging viable target in cancer and development of focal adhesion kinase inhibitors.
Chauhan A; Khan T
Chem Biol Drug Des; 2021 Mar; 97(3):774-794. PubMed ID: 33191630
[TBL] [Abstract][Full Text] [Related]
7. Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment.
Wu X; Wang J; Liang Q; Tong R; Huang J; Yang X; Xu Y; Wang W; Sun M; Shi J
Biomed Pharmacother; 2022 Jul; 151():113116. PubMed ID: 35598365
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.
Fang DD; Tao R; Wang G; Li Y; Zhang K; Xu C; Zhai G; Wang Q; Wang J; Tang C; Min P; Xiong D; Chen J; Wang S; Yang D; Zhai Y
BMC Cancer; 2022 Jul; 22(1):752. PubMed ID: 35820889
[TBL] [Abstract][Full Text] [Related]
9. EXOC4 Promotes Diffuse-Type Gastric Cancer Metastasis via Activating FAK Signal.
Li H; Fu X; Zhao J; Li C; Li L; Xia P; Guo J; Wei W; Zeng R; Wu J; Sun Y; Huang L; Wang X
Mol Cancer Res; 2022 Jul; 20(7):1021-1034. PubMed ID: 35471457
[TBL] [Abstract][Full Text] [Related]
10. Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review.
Shanthi E; Krishna MH; Arunesh GM; Venkateswara Reddy K; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Oct; 24(10):1077-100. PubMed ID: 25113248
[TBL] [Abstract][Full Text] [Related]
11. Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors.
Yamaguchi H; Takanashi M; Yoshida N; Ito Y; Kamata R; Fukami K; Yanagihara K; Sakai R
Cancer Sci; 2014 May; 105(5):528-36. PubMed ID: 24612061
[TBL] [Abstract][Full Text] [Related]
12. Focal adhesion kinase inhibitors in the treatment of solid tumors: Preclinical and clinical evidence.
Quispe PA; Lavecchia MJ; León IE
Drug Discov Today; 2022 Feb; 27(2):664-674. PubMed ID: 34856395
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances of Small Molecule Focal Adhesion Kinase (FAK) Inhibitors as Promising Anticancer Therapeutics.
Lv P; Chen K; Zhu HL
Curr Med Chem; 2021 Oct; 28(34):6977-6989. PubMed ID: 33797359
[TBL] [Abstract][Full Text] [Related]
14. Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy.
Heffler M; Golubovskaya VM; Dunn KM; Cance W
Cancer Biol Ther; 2013 Aug; 14(8):761-72. PubMed ID: 23792569
[TBL] [Abstract][Full Text] [Related]
15. Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK).
Lu Y; Sun H
J Med Chem; 2020 Dec; 63(23):14382-14403. PubMed ID: 33058670
[TBL] [Abstract][Full Text] [Related]
16. Focal adhesion kinase regulates collagen I-induced airway smooth muscle phenotype switching.
Dekkers BG; Spanjer AI; van der Schuyt RD; Kuik WJ; Zaagsma J; Meurs H
J Pharmacol Exp Ther; 2013 Jul; 346(1):86-95. PubMed ID: 23591997
[TBL] [Abstract][Full Text] [Related]
17. IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.
Lu H; Wang L; Gao W; Meng J; Dai B; Wu S; Minna J; Roth JA; Hofstetter WL; Swisher SG; Fang B
Mol Cancer Ther; 2013 Dec; 12(12):2864-73. PubMed ID: 24130049
[TBL] [Abstract][Full Text] [Related]
18. Development and Characterization of Selective FAK Inhibitors and PROTACs with In Vivo Activity.
Koide E; Mohardt ML; Doctor ZM; Yang A; Hao M; Donovan KA; Kuismi CC; Nelson AJ; Abell K; Aguiar M; Che J; Stokes MP; Zhang T; Aguirre AJ; Fischer ES; Gray NS; Jiang B; Nabet B
Chembiochem; 2023 Oct; 24(19):e202300141. PubMed ID: 37088717
[TBL] [Abstract][Full Text] [Related]
19. Focal adhesion kinase as a cancer therapy target.
Golubovskaya VM
Anticancer Agents Med Chem; 2010 Dec; 10(10):735-41. PubMed ID: 21214510
[TBL] [Abstract][Full Text] [Related]
20. Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights.
Yoon H; Dehart JP; Murphy JM; Lim ST
J Histochem Cytochem; 2015 Feb; 63(2):114-28. PubMed ID: 25380750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
